Faeth Therapeutics, Inc. (FTH) Institutional Shareholders

Faeth Therapeutics, Inc. (FTH) is currently reported in institutional portfolios tracked by InsiderSet based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026. The institutional investors covered on this page collectively reported approximately $321.22M in FTH holdings during the latest filing period.

Suvretta Capital Management, Llc is currently the largest disclosed institutional shareholder of FTH tracked by InsiderSet, reporting ownership valued at approximately $50.50M in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $69.69M, representing an estimated gain of +38.00% since the filing period.

The top 10 institutional shareholders tracked on this page collectively account for approximately 77% of the total disclosed FTH value among the investors covered in this analysis. Major shareholders include Suvretta Capital Management, Llc, Avoro Capital Advisors Llc, Baker Bros. Advisors Lp, and several other long-term asset managers with concentrated positions in Faeth Therapeutics, Inc. (FTH).

This page ranks the largest institutional FTH shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.

Institutional Holders

44

Total Reported Value

$321.22M

Largest Holder

Suvretta Capital Management, Llc

Largest Position

$50.50M

Insider Transactions (90d)

0

Latest Filing Quarter

Q2 2026

New Institutional Positions

55

Funds Exiting Positions

0

NameInvestor/ManagerPortfolio %QuantityReported BalanceCurrent Estimated ValueGain/loss Since FilingEstimated Portfolio Performance
Suvretta Capital Management, Llc1.06%2,020,103$50,502,575$69,693,554+$19,190,979+38.00%
Avoro Capital Advisors Llc0.32%1,444,039$36,100,975$49,819,346+$13,718,371+38.00%
Baker Bros. Advisors Lp0.16%1,286,411$32,160,275$44,381,180+$12,220,905+38.00%
Balyasny Asset Management L.P.0.05%1,042,198$26,054,950$35,955,831+$9,900,881+38.00%
Fairmount Funds Management Llc1.19%722,020$18,050,500$24,909,690+$6,859,190+38.00%
Logos Global Management Lp0.78%722,020$18,050,500$24,909,690+$6,859,190+38.00%
Ra Capital Management, L.P.0.16%722,020$18,050,500$24,909,690+$6,859,190+38.00%
Vivo Capital, Llc1.65%722,020$18,050,500$24,909,690+$6,859,190+38.00%
Caligan Partners Lp0.76%629,467$15,736,675$21,716,612+$5,979,937+38.00%
B Group, Inc.8.66%610,169$15,254,225$21,050,831+$5,796,606+38.00%
Trails Edge Capital Partners, Lp2.05%515,335$12,883,375$17,779,058+$4,895,683+38.00%
Adar1 Capital Management, Llc0.42%361,010$9,025,250$12,454,845+$3,429,595+38.00%
Octagon Capital Advisors Lp0.83%361,010$9,025,250$12,454,845+$3,429,595+38.00%
Cormorant Asset Management, Lp0.39%1,028,242$7,655,550$35,474,349+$27,818,799+363.38%
Marshall Wace, Llp0.00%206,508$5,162,700$7,124,526+$1,961,826+38.00%
Boxer Capital Management, Llc0.34%180,505$4,512,625$6,227,423+$1,714,798+38.00%
Patient Square Capital Lp0.68%175,050$4,376,250$6,039,225+$1,662,975+38.00%
Affinity Asset Advisors, Llc0.18%144,404$3,610,100$4,981,938+$1,371,838+38.00%
Alyeska Investment Group, L.P.0.01%144,404$3,610,100$4,981,938+$1,371,838+38.00%
Boothbay Fund Management, Llc0.06%133,643$3,341,075$4,610,684+$1,269,609+38.00%
Awm Investment Company, Inc.0.24%111,343$2,783,575$3,841,334+$1,057,759+38.00%
Richmond Investment Services, Llc0.63%79,731$1,993,275$2,750,720+$757,445+38.00%
Ikarian Capital, Llc0.14%35,386$884,650$1,220,817+$336,167+38.00%
Ubs Group Ag0.00%21,541$538,525$743,165+$204,640+38.00%
Renaissance Technologies LLCJim Simons0.00%20,416$510,400$704,352+$193,952+38.00%
Jane Street Group, Llc0.00%20,117$502,906$694,037+$191,131+38.01%
Morgan Stanley0.00%17,329$433,225$597,851+$164,626+38.00%
Geode Capital Management, Llc0.00%14,616$365,441$504,252+$138,811+37.98%
Superstring Capital Management Lp0.22%14,175$354,375$489,038+$134,663+38.00%
Barclays Plc0.00%12,412$310,300$428,214+$117,914+38.00%
Citadel Advisors Llc0.00%12,296$307,400$424,212+$116,812+38.00%
Vanguard Capital Management Llc0.00%10,115$252,875$348,968+$96,093+38.00%
Xtx Topco Ltd0.00%9,608$240,200$331,476+$91,276+38.00%
Vanguard Fiduciary Trust Co0.00%6,307$157,675$217,592+$59,917+38.00%
Catalio Capital Management, Lp0.03%14,718$157,041$507,771+$350,730+223.34%
China Universal Asset Management Co., Ltd.0.01%3,600$90,000$124,200+$34,200+38.00%
Blackrock, Inc.0.00%3,402$85,050$117,369+$32,319+38.00%
Tower Research Capital Llc (Trc)0.00%650$16,250$22,425+$6,175+38.00%
Royal Bank Of Canada0.00%509$13,000$17,561+$4,561+35.08%
Bnp Paribas Financial Markets0.00%113$2,825$3,899+$1,074+38.00%
Jpmorgan Chase & Co0.00%40$929$1,380+$451+48.55%
Quarry Lp0.00%32$800$1,104+$304+38.00%
Physician Wealth Advisors, Inc.0.00%28$700$966+$266+38.00%
Sbi Securities Co., Ltd.0.00%4$100$138+$38+38.00%
Showing 44 of 44

Frequently asked questions about FTH

  • Who owns the most FTH stock?

    The largest holders of FTH are typically major institutional investors such as asset managers and hedge funds reporting on Form 13F. The table above ranks tracked superinvestors by reported position size using the latest available filings for Faeth Therapeutics, Inc. (FTH).

  • Is FTH widely held by superinvestors?

    Many widely followed stocks like FTH appear across numerous superinvestor portfolios because of liquidity, index inclusion, and fundamentals. The holder count and table above show how broadly FTH is represented among the institutional managers we track.

  • What do “Current Estimated Value”, “Gain/loss Since Filing”, and “Estimated Portfolio Performance” mean?

    Current Estimated Value is reported share quantity from the latest 13F times our most recent split-adjusted U.S. session close. Gain/loss Since Filing is that estimate minus the reported 13F dollar value; Estimated Portfolio Performance is that difference as a percent of the reported value. Green means the estimate is above the filing value; red means below (not purchase cost). If many filers share the same implied filing price per share, the performance % may match across rows. These are not official fund marks or live quotes.